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Abstract
Small molecules have been shown to be potent and selective probes to understand cell physiology. Here, we show that
imidazo[1,2-a]pyridines and imidazo[1,2-a]pyrimidines compose a class of compounds that target essential, conserved
cellular processes. Using validated chemogenomic assays in Saccharomyces cerevisiae, we discovered that two closely
related compounds, an imidazo[1,2-a]pyridine and -pyrimidine that differ by a single atom, have distinctly different
mechanisms of action in vivo. 2-phenyl-3-nitroso-imidazo[1,2-a]pyridine was toxic to yeast strains with defects in electron
transport and mitochondrial functions and caused mitochondrial fragmentation, suggesting that compound 13 acts by
disrupting mitochondria. By contrast, 2-phenyl-3-nitroso-imidazo[1,2-a]pyrimidine acted as a DNA poison, causing damage
to the nuclear DNA and inducing mutagenesis. We compared compound 15 to known chemotherapeutics and found
resistance required intact DNA repair pathways. Thus, subtle changes in the structure of imidazo-pyridines and -pyrimidines
dramatically alter both the intracellular targeting of these compounds and their effects in vivo. Of particular interest, these
different modes of action were evident in experiments on human cells, suggesting that chemical–genetic profiles obtained
in yeast are recapitulated in cultured cells, indicating that our observations in yeast can: (1) be leveraged to determine
mechanism of action in mammalian cells and (2) suggest novel structure–activity relationships.
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Introduction
Chemical-genetic technologies in the baker’s yeast Saccharomyces
cerevisiae have proven to be a powerful means to study the mode of
action of biologically active compounds (reviewed in [1,2]). When
performed on a whole-genome scale, these methodologies typically
rely on the collection of yeast gene deletion mutant strains [3],
comparing the growth of each gene deletion strain to a wild type
strain in the presence and absence of compound. The throughput
of the technology was improved by applying a competitive growth
strategy, in which a pool of all deletion mutants is grown in the
presence and absence of compound [4–7]. Following growth,
deletion strains that are under-represented, and therefore sensitive,
in the presence of compound relative to the control condition are
identified by hybridizing the unique DNA sequences which flank
each deletion to their complements on a microarray [3].
Compounds can be grouped according to the similarities of their
chemo-genomic profiles, which is the total spectrum of gene
deletions that result in sensitivity to a given compound, to reveal
similarities in the biological responses to query compounds [8–11].
Chemical-genetic profiling has proven useful in the identification
of targets of a variety of different compounds in yeast [4,5,8,10].
Classic studies, including those indicating conservation of
rapamycin and FK-506 targets between mammalian and yeast
cells [12–14], encourage the view that chemical-genetic profiles
derived in yeast can reflect mode of action in human cells.
In this study we sought to provide molecular insight into the
biological activity of a group of imidazo[1,2-a]pyridines (IP) and
imidazo[1,2-a]pyrimidines (IPM). Members of this family of
compounds have been widely used in medicinal chemistry and
include pharmacological agents such as the phosphodiesterase 3
inhibitor olprinone [15], the hypnotic zolpidem [16], and the
anxiolytic divaplon [17]. Members also exhibit analgesic, anti-
inflammatory [18], anti-viral [19,20], and anti-microbial activities
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inhibitors [25] and as GABA receptor ligands [26,27]. Thus, these
compounds appear to target diverse cellular processes.
Previous studies have indicated that changes in the functional
group at position 3 and the atom at position 8 have varying effects
on antibacterial activity [21,22,24]. Here we investigate the
properties of eight imidazo[1,2-a]pyridines and imidazo[1,2-
a]pyrimidines. Only the 3-nitroso derivatives had significant
bioactivity in yeast. Chemical-genetic profiling revealed that the
atom at position 8 had a dramatic effect on the mode of action of
these compounds. 3-nitroso-imidazo[1,2-a]pyridine compromised
mitochondrial integrity and function whereas 3-nitroso-imi-
dazo[1,2-a]pyrimidine caused nuclear DNA damage. Of particu-
lar interest, these differences were recapitulated in human cells,
suggesting that the underlying mechanisms of action are
conserved. The analysis of these two compounds illustrates the
power of chemical-genetic screens in predicting the mode of action
of chemical compounds, and demonstrates that chemical-genetic
profiles from yeast can be used to gain insight into mode of action
in human cells.
Results
Antifungal Activity of Imidazo[1,2-a]pyridines and
Imidazo[1,2-a]pyrimidines
Eight IP or IPM derivatives (Figure 1A) were tested for toxicity
against budding yeast (Saccharomyces cerevisiae) cells. Cells were
cultured in the presence of 50 mM of each compound and assayed
for growth inhibition in liquid culture (Figure 1B, D). Only
compounds 13 and 15, each bearing a nitroso group at position 3,
were toxic to yeast cells at 50 mM, consistent with previous
observations that the substituent at position 3 is important for
activity of IPMs against pathogenic fungi [21]. Higher concentra-
tions (100 mg/ml; 0.4–0.5 mM) of compounds 14, 16, 17, and 18
did not inhibit growth significantly (Figure S1). Various modifi-
cations of the nitroso group or elimination of the benzene ring
eliminated anti-fungal activity. Nitroso aromatic compounds are
bioactive mainly because they are readily reduced to highly
reactive nitro radical anions which activate oxygen [28]. Several
lines of evidence suggest that compound 13 and 15 are acting as
oxidizing agents in vivo. 2-phenylimidazo[1,2-a]pyridin-3-amine
(compound 151), which is the reduced form of compound 13, was
not active on yeast cells (Figure 1B). Furthermore, the antifungal
activity of compound 13 and 15 could be partially suppressed by
pre-treating cells to induce intracellular accumulation of reduced
glutathione (Figure S2), a protective small molecule that is part of
the cellular defense against oxidative damage [29]. Finally, we also
found that chemical reduction of compounds 13 and 15 in vitro
resulted in their inactivation (data not shown).
Compound 13, the IP, was more potent than compound 15, the
IPM (Figure 1E). The concentration at which cells retain 50%
viability (EC50) for compound 13 was 9 mM, compared to 56 mM
for compound 15. Subsequent experiments were performed using
the same effective concentration for each compound.
Chemical–Genetic Screens with Compounds 13 and 15
Chemical-genetic screens have successfully predicted the
mechanism of action of a variety of compounds in yeast cells
[4–6,8,10]. To determine the molecular basis for the action of
compounds 13 and 15, we used the complete pool of barcoded
homozygous and essential heterozygous diploid deletion strains of
S. cerevisiae to identify gene deletions that confer sensitivity to each
compound (Figure 2A, B).
Deletion of genes involved in electron transport and mitochondrial
function caused cells to be sensitive to compound 13, illustrating the
importance of mitochondrial function in resistance to this compound
(Figure 2A). Of the 50 most sensitive gene deletions, 38 (76%) have
known roles in the mitochondria. Analysis of genes with a z-score
greater than 4 (120 genes) revealed a statistically significant
enrichment for Gene Ontology (GO) biological process terms
relevant to mitochondrial function (Figure 2C), including cellular
respiration, generation of energy, oxidative phosphorylation, and
mitochondrial genome maintenance. The most enriched GO process
was translation, likely due to the abundance of mitochondrial tRNA
synthetase and mitochondrial ribosome gene deletion strains
identified as sensitive in the screen.
By contrast, profiling of compound 15 revealed that deletions of
DNA repair genes, notably those involved in nucleotide excision
repair (NER), post replication repair (PRR), and homologous
recombination (HR) conferred sensitivity to this compound
(Figure 2B). Enriched GO biological processes in the top hits (z-
score.4; 45 genes) included response to DNA damage, DNA
repair, nucleotide excision repair, and DNA recombination
(Figure 2D). The observation that NER, PRR, and HR mutants
are all sensitive to compound 15 is reminiscent of tolerance of
damage caused by cisplatin, which requires all three of these repair
pathways [30–33]. NER mutants were most sensitive to com-
pound 15, indicating that NER genes are likely to be the first line
of defense against damage caused by compound 15. NER is
involved in removal of bulky helix-distorting lesions and adducts
on DNA [34,35], which suggests that compound 15 might directly
modify DNA in cells to cause this type of damage.
Hierarchical Clustering of Compound 13 and 15 with a
Compendium of Compounds
Two-dimensional hierarchical clustering was performed for
compound 13 and 15, using a compendium of chemical-genetic
profiles [8,10] obtained for a diverse collection of bioactive
compounds (Figure 3A). Chemical-genetic profiles of haploid
deletion mutants of non-essential genes were subjected to
clustering analysis, in which compounds with similar mechanisms
of action cluster together on one axis, and genes with similar
spectrums of sensitivities to the compounds cluster together on the
other axis.
Author Summary
We have shown that chemical–genetic screening allows
structure–activity studies of chemical compounds at a very
high resolution. In analyzing the effects of closely related
imidazo-pyridine and -pyrimidine compounds, we found
two compounds that likely act as oxidizing agents, yet
target different organelles. The imidazo-pyridine affected
mitochondrial functions whereas the imidazo-pyrimidine
caused nuclear DNA damage. Remarkably, the only
difference between these two compounds is the presence
of a nitrogen atom at position 8. Thus, in addition to
demonstrating the potential for high resolution in
chemical–genetic studies, our work suggests that subtle
changes in compound chemistry can be exploited to
target different intracellular compartments with very
different biological effects. Finally, we show that chemi-
cal–genetic profiling in yeast can be used to infer mode of
action in mammalian cells. The specificity of compound 15
in eliciting a nuclear DNA damage response in evolution-
arily diverse eukaryotes suggests that it will be of great
utility in studying the cellular response to nuclear oxidative
damage.
Chemical-Genetic Profiling Reveals Target Pathways
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sensitivity to each compound, clustering analysis suggested two
very different mechanisms of action for compounds 13 and 15.
The profile of compound 13 clustered with carbonyl cyanide para-
trifluoromethoxyphenylhydrazone (FCCP), sodium azide, and
hydrogen peroxide (Figure 3A). FCCP is a proton ionophore
and sodium azide is a respiratory chain inhibitor, suggesting that
compound 13 might depolarize the mitochondrial membrane.
Compound 13 also clustered with hydrogen peroxide, an oxidizing
agent whose tolerance requires functional mitochondria [36]. The
genes identified in the compound 13 screen overlapped signifi-
cantly with those identified in hydrogen peroxide screens reported
by Thorpe et al. and Tucker and Fields (p=2.33610
236 and
p=5.91610
223, respectively) [37,38], further suggesting that
compound 13 may be peroxide-like in its character (Figure 3B).
The genes identified in the compound 15 screen showed no
significant overlap with the reported H2O2 screens (Figure 3B).
The chemical-genetic profile of compound 15 clustered most
closely to cisplatin, which forms both intra-strand and inter-strand
DNA crosslinks [39,40]. It also clustered close to the alkylating
agent methyl methanesulfonate (MMS), the topoisomerase
inhibitor camptothecin, the replication inhibitor hydroxyurea,
and the DNA crosslinking agent mitomycin C, all of which cause
DNA damage (Figure 3A). Based on these results, and the
enrichment of GO processes evident in the chemical-genetic
screens, we hypothesize that compound 13 disrupts mitochondrial
function whereas compound 15 causes nuclear DNA damage.
Thus despite differing by only a nitrogen atom at position 8, these
compounds appear to target different intracellular compartments.
Although the mechanism by which this differential targeting
occurs remains to be determined, one interesting possibility is that
different chemical rearrangements might be responsible for the
preferential targeting observed for compounds 13 and 15. Unlike
imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrimidines are suscepti-
ble to nucleophilic recyclizations, as the pyrimidine ring makes the
system p-deficient [41].
Compound 13 Disrupts Mitochondrial Function
Our chemical-genetic analysis indicated that compound 13 is
peroxide-like in character. To determine if hydrogen peroxide and
compound 13 induce similar cellular responses, we tested if
inducing an oxidative stress response by pretreatment of cells with
Figure 1. Yeast bioactivity of imidazo-pyridine and imidazo-pyrimidine compounds. A. Structures and synthesis of the imidazo-pyridine
compounds analyzed. B. Compound 13 inhibits yeast growth. Cultures of S. cerevisiae were grown in the presence of 50 mM of the imidazo-pyridine
compounds. Optical density was measured every 2 hours to follow cell growth. C. Structures and synthesis of the imidazo-pyrimidine compounds
analyzed. D. Compound 15 inhibits yeast growth. Cultures of S. cerevisiae were grown in the presence of 50 mM of the imidazo-pyrimidine
compounds. Optical density was measured every 2 hours to follow cell growth. E. EC50 determination for compound 13 and compound 15. Cells were
treated with the indicated concentrations of the respective compounds for two hours and plated on rich media to determine colony-forming units.
Viability is expressed relative to the untreated (vehicle only) control.
doi:10.1371/journal.pgen.1000284.g001
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subsequent treatment with compound 13 (Figure 4A). This
adaptive response has been observed for H2O2 in both prokaryotes
and eukaryotes [42–45]. Cells were pretreated with sub-lethal
concentrations of H2O2 for one hour and then subjected to
compound 13, compound 15, or a higher concentration of H2O2.
The adaptive response was measured in liquid growth assays,
comparing untreated and H2O2 pre-treated cells (Figure 4A). A
slope of 1.0 indicates that pre-treatment had no effect on the
growth rate of cells (Figure 4A, control). Pre-treatment with H2O2
conferred tolerance to H2O2 and compound 13, resulting in slopes
of greater than 1.0 (Figure 4A). Thus, induction of an oxidative
stress response by pre-treatment with H2O2 results in tolerance to
subsequent treatment with compound 13, suggesting that the
cellular response to these compounds is similar.
Since H2O2 tolerance requires functional mitochondria [36],
sensitivity to H2O2 can be used as a proxy measure of
mitochondrial function. We tested the effect of pre-treatment of
cells with compound 13 on H2O2 sensitivity (Figure 4B). Cells
were treated with compound 13 or 15, or ethidium bromide or the
proton ionophore FCCP. Treatment with ethidium bromide or
FCCP, which compromise mitochondrial function by different
mechanisms, resulted in a greater sensitivity to H2O2 using halo
assays (Figure 4B). Similarly, compound 13 treatment produced a
larger clearing than the vehicle (DMSO), suggesting that
compound 13 compromises mitochondrial function.
Our accumulated evidence that compound 13 impairs mito-
chondrial function prompted us to examine whether this
compound perturbs mitochondrial morphology (Figure 4C). Yeast
cells expressing GFP targeted to the mitochondria were grown in
the presence of the vehicle DMSO, compound 13, or compound
15, and mitochondrial morphology was examined by fluorescence
microscopy. Upon treatment with DMSO or compound 15
(Figure 4C), most cells exhibited the normal mitochondrial
morphology consisting of branched tubular network at the cell
cortex [46,47]. However, 80% of cells treated with compound 13
showed punctate fragmented mitochondria (Figure 4C). Thus,
compound 13 caused fragmentation of the mitochondria, a
phenotype consistent with impaired mitochondrial function.
Compound 15 Tolerance Requires DNA Repair Pathways
Chemical-genetic analysis indicated that genes involved in three
different DNA damage repair pathways are needed for cellular
resistance to compound 15. We confirmed the sensitivity of the top
hits from the screen with spot dilution assays using individual
deletion strains (Figure 5A). Ten-fold serial dilutions of cells were
spotted on solid media containing either the vehicle DMSO,
compound 13, or compound 15. Since compound 13 and 15 have
significantly different potency (Figure 1E), they were used at 8% of
their respective EC50’s (0.72 mM for compound 13 and 4.45 mM
for compound 15). Deletion of genes involved in NER, PRR, and
HR conferred sensitivity to compound 15. NER mutants were, in
Figure 2. Chemical-genetic profiling of compound 13 and compound 15. A. Identification of gene deletion mutants that confer sensitivity to
9 mM compound 13 by chemical-genetic profiling with the yeast heterozygous essential gene deletion mutants and the homozygous diploid non-
essential gene deletion mutants. Fitness defect scores are calculated based on barcode microarray hybridization, and are plotted on the y-axis.
Positive values indicate under-representation in the treated pool, and therefore sensitivity of the corresponding mutant. The heterozygous (first 1200
genes) and homozygous deletion mutants are arranged on the x-axis alphabetically. Essential genes (purple), electron transport genes (red) and
genes annotated for mitochondrial function (yellow) in the top 50 hits are indicated. B. Identification of gene deletion mutants that confer sensitivity
to 9 mM compound 15. Essential genes (purple), nucleotide excision repair genes (NER; red) and DNA repair genes (yellow) in the top 50 hits are
indicated. C. Enrichment of GO biological processes in compound 13 sensitive strains with a fitness defect score greater than 4. D. Enrichment of GO
biological processes in compound 15 sensitive strains with a fitness defect score greater than 4.
doi:10.1371/journal.pgen.1000284.g002
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chemical-genetic screens. PPR and HR mutants were less sensitive
to compound 15, with the upstream genes in each pathway being
more sensitive than downstream genes (e.g., rad5D was the most
sensitive PRR mutant, and xrs2D and mre11D were the most
sensitive HR mutants). Thus, this individual strain analysis not
only confirmed the results of the chemical-genetic screens, but also
confirmed that tolerance of compound 15 requires DNA repair
pathways, whereas tolerance of compound 13 does not.
Compound 15 Activates the DNA Damage Checkpoint
The DNA damage checkpoint is a signal transduction pathway
that is activated in response to DNA damage (reviewed in [48]). We
tested whether compound 15 activates the DNA damage checkpoint
Figure 3. Two-dimensional hierarchical clustering of compounds 13 and 15 with the chemical-genetic profiles of a compendium of
102 compounds and extracts. A. 3418 genes are plotted on the horizontal axis with the gene cluster tree across the top. Compounds are plotted
on the vertical axis with the cluster tree on the right. Chemical-genetic interactions are represented as red lines. A portion of the cluster, with 46
compounds, is shown. B. Overlap between the compound 13 and the compound 15 profiles, and the profiles of H2O2 described in the literature
[37,38]. The Venn diagrams show the number of genes out of a possible 4944 non-essential genes that were identified as being sensitive to
compound in each study.
doi:10.1371/journal.pgen.1000284.g003
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DNA damage is correlated with its phosphorylation, and this results
in slower mobility of the protein during SDS-PAGE [49–51]. When
logarithmic phase cultures were treated with the DNA damaging
agent MMS or with compound 15, we observed the characteristic
mobility shift of Rad53, indicating checkpoint activation (Figure 5B).
Compound 13 did not cause Rad53 activation. We also observed a
mobility shift in both the G1 and G2/M arrested cells following
treatment with compound 15, whereas MMS did not activate Rad53
in either arrested sample (Figure 5B).We conclude that compound 15
Figure 4. Compound 13 impairs mitochondrial function. A. Pre-treatment with sublethal concentrations of H2O2 induces tolerance of
compound 13. Cells were treated with a sub-lethal (0.25 mM) concentration of H2O2 for one hour before treatment with higher concentrations of
H2O2 (0 to 3.0 mM, in 1.25-fold increments), compound 13 (0 to 13.4 mM, in 1.25-fold increments), or compound 15. Growth of pre-treated cells
relative to untreated cells is plotted. B. Compound 13 causes peroxide sensitivity. Cells were pre-treated with 1% DMSO, 9 mM compound 13, 56 mM
compound 15, 25 mM ethidium bromide, 1% MeOH, or 15.7 mM FCCP and spread on YPD plates. Disks containing 6% H2O2 were placed in the center
of each plate and the zone of growth inhibition was measured. The average of two independent experiments is plotted, and error bars span one
standard deviation. C. Compound 13 causes mitochondrial fragmentation. Cells were treated with 1% DMSO, 9 mM compound 13, or 56 mM
compound 15 for three hours. Mitochondrial morphology was evaluated by fluorescence microscopy, detecting mitochondrial targeted GFP. The
fraction of cells displaying the normal tubular mitochondrial morphology and the fraction showing punctate mitochondrial morphology is plotted.
doi:10.1371/journal.pgen.1000284.g004
Figure 5. Compound 15 causes nuclear DNA damage in vivo. A. DNA repair mutants are sensitive to compound 15. Ten-fold serial dilutions of
the indicated deletion mutant strains were spotted on media containing 1% DMSO, 0.7 mM compound 13 (0.08 EC50), or 4.5 mM compound 15 (0.08
EC50). Mutants in nucleotide excision repair (NER), postreplication repair (PRR), and homologous recombination repair (HR) are indicated. B.
Compound 15 activates the DNA damage checkpoint kinase Rad53. Asynchronous populations of cells (asyn), or cells arrested in G1 (aF) or G2/M
(noc), were treated with 56 mM compound 15, or with 0.035% MMS, for 2 hours. Following TCA fixation, cell extracts were fractionated on SDS-PAGE
and Rad53 was detected by immunoblot analysis. The effect of the vehicle DMSO (D) is also shown. C. Compound 15 induces mutagenesis. Cells were
treated with vehicle (DMSO), 0.035% MMS, 9 mM compound 13, or 56 mM compound 15 for 2 hours. The average mutation rate is plotted, with error
bars spanning one standard deviation.
doi:10.1371/journal.pgen.1000284.g005
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not require passage through S phase it is therefore likely the result of
compound 15 causing DNA damage rather than DNA replication
stress.
We next assessed the downstream effects of DNA damage caused
by compound 15. Since compounds that damage DNA can induce
mutagenesis [52,53], we measured the mutation rate in a wild type
strain following treatment with compounds 13 or 15, the DNA
alkylating agent MMS, or DMSO, assessing forward mutation to
canavanine resistance (Figure 5C). Cells treated with compound 13
had a mutation rate similar to that of DMSO treated cells, while
cells treated with compound 15 had an approximately three-fold
increase in mutation rate. Thus, compound 15, but not compound
13, induced mutagenesis of nuclear genes, consistent with
compound 15 damaging nuclear DNA in vivo.
The Modes of Action of Compounds 13 and 15 Are
Recapitulated in Human Cells
To determine if the distinct actions of compounds 13 and 15 are
evident in mammalian cells, we treated Jurkat cells with increasing
concentrations of each compound and measured viability
(Figure 6A). Both compounds were toxic to human cells, but the
relative cytotoxicity was the reverse of what we observed in yeast,
with compound 15 having a lower EC50 (25 mM) than compound
13 (76 mM). A similar result was obtained with HeLa cells (data
not shown).
We first tested the effect of the two compounds on the
mitochondrial morphology of HeLa cells. We treated HeLa cells
with DMSO, compound 13, or compound 15 for 4 hours, and
observedmitochondrialmorphologybyindirectimmunofluorescent
detection of the ATP synthase (complex V) subunit a (Figure 6B).
For compound 13 treated cells, we observed a significant increase in
the number of cells with punctate, fragmented mitochondria,
reminiscent ofourobservation of fragmented mitochondria inyeast.
By contrast, compound 15 treated cells did not show an increase in
mitochondrial fragmentation.
We next tested whether either compound caused DNA damage
checkpoint activation, a marker for nuclear DNA damage. In
mammalian cells, DNA double strand breaks usually result in
activation of ATM, whereas ATR is activated in response to UV
Figure 6. Compound 13 induces mitochondrial fragmentation and compound 15 activates the DNA damage response in
mammalian cells. A. Viability of Jurkat cells following treatment with compound 13 or 15. Cells were grown in the presence of increasing
concentrations of compounds for two days and viability was measured. B. Mitochondrial morphology of HeLa cells following treatment with
compound 13 (45 mM), compound 15 (22.5 mM), or DMSO (0.2%). Mitochondria were stained with anti-ATP synthase (complex V) subunit a
antibodies. Deconvoluted optical sections of representative cells are shown (top). The fraction of cells containing punctate, fragmented mitochondria
or tubular mitochondria was determined by counting at least 200 cells in each experiment (bottom). C. Immunoblot detection of phosphorylated
forms of Chk2. Cells were treated with DMSO (0.2%), MMS (0.0035%), compound 13 (63 mM), or compound 15 (23 mM) for four hours. Cell extracts
were run on SDS-PAGE and probed with the respective Chk2 antibodies. D. Immunoblot detection of phosphorylated H2AX. Cells were treated as in
(B). Cell extracts were run on SDS-PAGE and probed with anti-phospho-H2AX antibodies. E. Viability of XPD and rescued XPD (XPD+ERCC2) lines
following treatment with the indicated concentrations of cisplatin or compound 15.
doi:10.1371/journal.pgen.1000284.g006
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activation whereas ATR is predominantly required for Chk1
activation, although there is some cross talk between the pathways
(reviewed in [54–56]). Jurkat cells were treated with vehicle, with
MMS as a positive control, or with compound 13 or 15
(Figure 6C). For cells treated with compound 15, we observed
robust phosphorylation of Chk2 with two phospho-specific Chk2
antibodies, indicating the activation of the DNA damage
checkpoint. We further tested these cells for phosphorylation of
histone H2AX, a chromatin modification that occurs near double
strand DNA breaks (reviewed in [57,58]). Like Chk2 phosphor-
ylation, H2AX phosphorylation was induced by compound 15,
but not by compound 13 (Figure 6D).
Finally, we asked whether nucleotide excision repair (NER) was
important for tolerance of DNA damage induced by compound 15
in mammalian cells, as was the case in yeast. NER genes are
mutant in the repair defective chromosome instability syndrome
Xeroderma Pigmentosum (XP) [59,60]. We utilized a cell line
from a patient of the XPD complementation group [61], mutant
in the ERCC2 DNA helicase [62], and a control line in which the
mutation was restored to the wild type by a transfected ERCC2
expression construct [63], and tested for sensitivity to compound
15, compound 13, and cisplatin. For both cisplatin and compound
15, expression of ERCC2 (XPD+ERCC2) rescued the sensitivity
of the NER-defective XPD cell line (XPD; Figure 6E). By contrast,
sensitivity to compound 13 was not efficiently rescued by
expression of ERCC2 (Figure S4). We conclude that the yeast
chemical-genetic profile accurately predicted an important role for
NER in the repair of DNA lesions induced by compound 15 in
mammalian cells.
Thus our observations in mammalian cells mirror those in yeast:
compound 13 causes mitochondrial fragmentation and compound
15 causes damage to the nuclear DNA that is repaired by the NER
pathway.
Discussion
Chemical-genetic profiling in yeast is a robust technique for
exploring the mechanism of action of biologically active
compounds. Profiling of compound 13 and 15, a nitroso-armed
imidazo-pyridine and imidazo-pyrimidine, respectively, suggested
that despite the strong likelihood that they cause oxidative stress,
they might act in a mechanistically distinct manner. We provide
several lines of evidence that compound 13 causes mitochondrial
dysfunction, whereas compound 15 causes damage to the nuclear
DNA. These different modes of action were also apparent when
human cells were treated with compounds 13 and 15, illustrating
the utility of chemical-genetic profiling in yeast in predicting mode
of action in higher eukaryotes.
Nitroso aromatic compounds are bioactive mainly because they
are readily reduced to highly reactive nitro radical anions which
activate oxygen [28]. Although there is a possibility that
compound 13 and 15 are toxic to cells via other mechanisms,
several lines of evidence suggest that compound 13 and 15 are
acting as oxidizing agents in vivo. We found that 2-phenylimi-
dazo[1,2-a]pyridin-3-amine (compound 151), which is the reduced
form of compound 13, was not active on yeast cells (Figure 1B).
Furthermore, the antifungal activity of compound 13 and 15 could
be partially suppressed by pre-treating cells to induce intracellular
accumulation of reduced glutathione (Figure S2), a protective
small molecule that is part of the cellular defense against oxidative
damage [29,64]. Finally, we also found that chemical reduction of
compounds 13 and 15 in vitro resulted in their inactivation (data
not shown).
The chemical-genetic profile of compound 13 was significantly
enriched for biological processes such as mitochondrial organiza-
tion and biogenesis, and oxidative phosphorylation. This profile is
reminiscent of that of H2O2 in which a specific requirement for an
intact respiratory chain [37] and a broader requirement for
mitochondrial function [38] was observed. Our data also suggest
that compound 13 causes mitochondrial dysfunction since cells
treated with compound 13 lose their peroxide tolerance, much like
those treated with ethidium bromide or the ionophore FCCP.
Consistent with this, compound 13 caused dramatic changes in
mitochondrial morphology, resulting in extensive mitochondrial
fragmentation, a phenotype known to disrupt mitochondrial
activity. Maintenance of proper mitochondrial morphology is
critical, and fragmentation of mitochondria is an important step in
the progression of apoptosis [65].
Compound 15 displayed none of the mitochondria-specific
characteristics seen with compound 13. The chemical-genetic
profile of compound 15 showed little overlap with that of
compound 13, and its profile clearly differed from other oxidizing
agents examined. Few DNA repair genes have been identified in
genome-wide screens with the oxidants H2O2, linoleic acid 13-
hydroperoxide, menadione, cumene hydroperoxide, and diamide
[37,38]. It has therefore been speculated that loss of viability
following treatment with these agents is due to damage to proteins
rather than to DNA [37]. Our evidence that compound 15 causes
DNA damage suggests that it will be a useful compound in the
study of the cellular response to oxidative damage in the nucleus.
Importantly, although targeting of oxidative stress to the nucleus
has been reported [66], we provide evidence of targeted oxidative
stress specifically causing nuclear DNA damage. Although this can
be readily inferred from the importance of three DNA repair
pathways in compound 15 tolerance, we also demonstrated that
compound 15 causes activation of the DNA damage checkpoint
and induces mutations in nuclear DNA.
The anti-proliferative and DNA damaging properties of
compound 15 are shared by a number of cancer therapeutics,
indicating that compound 15 or derivatives of it might be useful in
this regard. It is of particular interest that tolerance of compound
15 in mammalian cells required the same DNA repair pathway,
nucleotide excision repair, as was found in yeast. DNA repair
pathway-specific toxicity affords the possibility of rational
therapeutic approaches based on targeting cells defective in a
given pathway. Additionally, synergy might be obtained by
targeting multiple DNA repair pathways independently. Mito-
chondria are also an attractive anti-cancer target, as pharmaco-
logical modulation of mitochondrial permeability can result in
apoptotic cell death [67]. The mitochondrial fragmentation caused
by compound 13 might reflect induction of the permeability
transition pore, as has been observed with other forms of oxidative
stress [68]. Ongoing studies to determine the precise mechanism of
action of compound 13 will reveal its potential as a therapeutic.
Materials and Methods
Yeast Strains
The yeast strain BY4741 [69] was used in the growth rate study.
Gene deletion mutant strains [3] are available from Open
Biosystems. Standard yeast media and growth conditions were
used [70]. The rho
0 strain lacking mitochondrial DNA was
generated from BY4741 as described [71].
Compound Chemistry
Compounds 2, 3, 16 and 18 were synthesized by condensation
of the non-substituted 2-amino-pyridine (1a) or 2-amino-pyrimi-
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CO-R; R=Ph, p-MeO-Ph, CO2-Et), as reported [72–75]. 3-
formyl-2-(4-methoxyphenyl)imidazo[1,2-a]pyrimidine (14) and 3-
formyl-2-phenylimidazo[1,2-a]pyridine (17) were generated from
compounds 3 and 2 respectively as described [24]. Treatment of 2
and 18 with sodium nitrite in acetic acid under ambient
conditions, as reported [21], gave 13 and 15 respectively with
an overall yield of 70–80%. The reduction of the nitroso group at
position 3 of 13 was carried out with tin in HBr medium,
providing 151 with a yield of 90%. Acetylation of the amine group
of 151 by acetic anhydride gave a novel compound (152) bearing
an amide group at position 3. Further details are presented in the
Supplementary Methods (Text S1).
Growth and Viability Analysis
For the growth analysis the different compounds were added to
logarithmic phase cells and growth rate was monitored by
measuring the optical density of cells (OD600) as a function of
time (hours) in rich medium. All compounds were diluted in 100%
DMSO, and all assays, including the ‘‘no compound’’ control,
contained 1% DMSO.
For viability analysis, cells were grown in YPD [76] in the
presence of 0 to 15.6 mM compound 13, or 0 to 107 mM
compound 15, for 2 hours at 30uC. Cells were then spread on
YPD plates to determine the number of colony-forming units.
Chemical–Genetic Screens
Screens of the homozygous deletion pool, the heterozygous
deletion pool, and the haploid deletion pool were performed as
described [10,11], with 9 mM of compound 13 or compound 15,
which corresponded to 10% growth inhibition of the wild type
diploid. Fitness defect scores, based on a tag specific algorithm that
takes into account the intensities of each tag in the compound
treated cells compared to non-treated cells, were calculated for
each deletion strain in the pool for each experiment as described
[9]. The complete scores for the screens with compounds 13 and
15 are available at http://biochemistry.utoronto.ca/brown/data.
html. Microarray data have been deposited in the ArrayExpress
database (Accession numbers E-TABM-560 and A-MEXP-1420).
Two-dimensional hierarchical clustering was performed as
described [10]. Enrichment of GO terms was calculated from
the hypergeometric distribution. P indicates the probability that
each GO term would be expected by chance to occur at equal to
or greater than the observed frequency within an identified set of
genes, given the known frequency of occurrence among the genes
represented in the heterozygous and homozygous deletion mutant
pools. GO biological processes were filtered for processes
containing .400 or ,20 genes, to eliminate processes that are
too general or too specific.
Peroxide Response and Halo Assays
For peroxide adaptation experiments, log phase cells were
grown in YPD or YPD containing sub-lethal (0.25 mM)
concentration of H2O2 for one hour before treatment with higher
concentrations of H2O2 (0 to 3.0 mM, in 1.25-fold increments),
compound 13 (0 to 13.4 mM, in 1.25-fold increments), or
compound 15 (0 to 44.6 mM, in 1.25-fold increments). Optical
density was monitored for 24 hours. The adaptive response for
each concentration of compound was calculated by dividing the
time it takes for non pre-treated (or pre-treated) cells in the
presence of compound to reach an OD600 of 0.15 by the time it
takes the same cells in the absence of the compound to reach the
same OD.
Peroxide sensitivity was determined using halo assays. Wild type
cells were grown in the presence of 1% DMSO, 9 mM( 1E C 50)
compound 13, 56 mM( 1E C 50) compound 15, 25 mM ethidium
bromide, 1% MeOH (the vehicle for FCCP), or 15.74 mM FCCP
for 24 hours. Equal numbers of treated cells were spread onto
YPD plates and 8 mm Whatman disks containing 6% H2O2 were
put onto the middle of each plate. Plates were incubated at 30uC
for 2 days and then photographed. The diameter of the growth
inhibition was measured using OpenLab (ImproVision, Waltham,
MA), the area of inhibition was calculated, and plotted as the
average of two independent experiments.
Mitochondrial Morphology
Yeast mitochondria were visualized by transforming cells with
pVT100U-mtGFP [77] encoding mitochondria-targeted GFP.
Cells were treated with DMSO (1%), compound 13 (9 mM), or
compound 15 (56 mM) for three hours, and mitochondrial
morphology was observed by taking Z-sections of GFP fluores-
cence with an Imager Z1 Zeiss microscope using a 636objective
and deconvolution with ImproVision Velocity software. At least
three hundred cells of each compound treated sample were
counted and grouped either into normal tubular morphology, or
punctate morphology.
HeLa cell mitochondrial morphology was observed by indirect
immunofluorescence of the ATP synthase (complex V) subunit a
using CV-a antibody (Mitosciences, Oregon) as described by the
supplier, and quantified as described above.
Mutation Rate Analysis
Cells were treated with 1% DMSO, 0.035% MMS, 9 mM( 1
EC50) compound 13, or 56 mM( 1E C 50) compound 15 for
2 hours, and allowed to grow to saturation. Cells were plated on
complete and selective media to determine the frequency of
mutations in the CAN1 gene, as described previously [78].
Mutation rates were calculated using the method of the median
[79], and are averages of three fluctuation tests of 7 independent
assays.
Immunoblotting
Wild type yeast, or DNA repair mutants, were treated with 1%
DMSO, 0.035% MMS, 9 mM( 1E C 50) compound 13, or 56 mM
(1 EC50) compound 15 for 2 hrs. 1610
8 cells were TCA fixed,
collected, and used for Rad53 immunoblots, as described [80].
Rad53 was detected with yC-19 (Santa Cruz Biotechnology). Blots
were re-probed for Tub1 (YOL1/34; Novus Biologicals) as a
loading control.
Jurkat cells were grown in 0.2% DMSO, 0.0035%MMS,
63 mM compound 13, or 23 mM compound 15 for 4 hours,
washed with 16PBS, and extracts were made by lysing the cells in
SDS loading dye. Rabbit polyclonal antibodies against Chk2,
Phospho-Chk2 (Thr 68), and Phospho-Chk2 (Ser 33/35) were
from Cell Signaling Technology. Antibodies against phosphory-
lated H2AX (Ser139; clone JBW301) were from Millipore.
Mammalian Cells
Details of the growth and maintenance of Jurkat cells (ATCC),
HeLa cells (ATCC), and XPD lines GM08207 and GM15877
(Coriell Institute for Medical Research) are described in the
Supplementary Methods (Text S1).
Supporting Information
Figure S1 Yeast bioactivity of imidazo-pyridine and imidazo-
pyrimidine compounds. Cultures of S. cerevisiae were grown in the
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compound 13, included as a control at 20 mg/ml) and their optical
density was measured and compared to the untreated (DMSO
only) control at 4, 8, and 20 hours.
Found at: doi:10.1371/journal.pgen.1000284.s001 (0.05 MB PDF)
Figure S2 Induction of intracellular GSH increases tolerance of
compound 13 and 15. Growth of cells treated with DMSO (red
line), compounds (black line), or cells with increased intracellular
GSH in the presence of compounds (blue line) were monitored as
a function of time.
Found at: doi:10.1371/journal.pgen.1000284.s002 (0.08 MB PDF)
Figure S3 Compound 15 causes Rad53 activation in vivo. Cells
were treated with increasing amounts of either compound 13 or 15
and fixed with 10% TCA. Cell extracts were fractionated on SDS-
PAGE, and Rad53 protein detected by immunoblot analysis. The
positions of Rad53 and the activated, phosphorylated form of
Rad53 (Rad53-P) are indicated. The immunoblots were re-probed
to detect tubulin (tub), as a loading control. Compound 15
activated Rad53 at concentrations of 45 mM and 67.5 mM (0.8
EC
50 and 1.6 EC
50). By contrast, compound 13 did not induce
detectable Rad53 phosphorylation, even at 112.5 mM (12.5 EC
50).
Found at: doi:10.1371/journal.pgen.1000284.s003 (0.23 MB PDF)
Figure S4 ERCC2 expression does not significantly rescue
sensitivity of XPD cells to compound 13. Viability of XPD and
rescued XPD (XPD+ERCC2) lines was determined following
treatment with the indicated concentrations of compound 13.
Found at: doi:10.1371/journal.pgen.1000284.s004 (0.05 MB PDF)
Text S1 Supplemental methods.
Found at: doi:10.1371/journal.pgen.1000284.s005 (0.05 MB
DOC)
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